Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Financing Activities (2018 - 2025)

Zevra Therapeutics' Cash from Financing Activities history spans 11 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 219.85% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $12.1 million, down 85.31%, while the annual FY2025 figure was $12.1 million, 85.31% down from the prior year.
  • Cash from Financing Activities reached $2.5 million in Q4 2025 per ZVRA's latest filing, down from $6.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $74.3 million in Q1 2021 to a low of -$4.7 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $12.2 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: plummeted 6139.13% in 2021, then skyrocketed 7800.59% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$2.9 million in 2021, then surged by 88.68% to -$325000.0 in 2022, then soared by 1639.69% to $5.0 million in 2023, then tumbled by 84.09% to $796000.0 in 2024, then surged by 219.85% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cash from Financing Activities are $2.5 million (Q4 2025), $6.5 million (Q3 2025), and $1.4 million (Q2 2025).